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CASE REPORT

A Novel Mutation in the Choroideremia Gene in a Turkish Family
Mustafa Iftikhar1, Yulia Wolfson2, Simrat Sodhi2, Bushra Usmani1, Hendrik P. N. Scholl2 and Syed M.A. Shah3

ABSTRACT
Choroideremia is an X-linked recessive genetic disorder caused by mutations in the CHM gene. It is a rare retinal
dystrophy that manifests as nyctalopia and vision loss, progressing to blindness in later stages. We report a 21-year
Turkish man who presented with nyctalopia for the past 4-5 years. His mother and maternal grandmother had similar, but
less pronounced complaints. Fundus examination revealed pigmentary changes and retinal atrophy in both eyes. Optical
coherence tomography showed outer retinal loss, with central island of preserved autofluorescence surrounded by absent
autofluorescence on fundus autofluorescence examination. Goldmann visual fields were constricted. Microperimetry
detected retinal sensitivity losses, and full-field electroretinogram demonstrated extinguished cone responses. Genetic
analysis revealed a novel nonsense mutation in the CHM gene, namely p.E480X: c.1438G >T. The mutation causes a
premature stop codon in exon 12. This is the first report of a G1438T mutation resulting in an E480X premature stop in
the CHM gene.
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INTRODUCTION

CASE REPORT

Choroideremia is a rare (1:50,000 males) X-linked
recessive retinal dystrophy caused by mutations in the
CHM gene (Xq21), which encodes component A of Rab
geranyl-geranyl-transferase, also referred to as Rab
escort protein-1 (REP-1).1 It is characterised by
progressive chorioretinal degeneration with early retinal
thickening, followed by photoreceptor degeneration,
retinal pigment epithelium (RPE) depigmentation and
retinal remodelling.1 Clinical manifestations include
nyctalopia and peripheral vision loss which gradually
progress to central vision loss and eventual blindness in
the later stages of the disease.1 The disease primarily
affects males, although female carriers can demonstrate
patchy chorioretinal atrophy, with either no symptoms or
a mild degree of nyctalopia.

A 21-year man from a Turkish family presented to the
Hospital for difficulty seeing in the dark for the past 4-5
years and reported a recent diagnosis of choroideremia
in Turkey. The patient had no other complaints and his
past medical history was unremarkable.

To date, many mutations in the CHM gene have been
identified in different ethnic populations, including
deletions, insertions, duplications, translocations, splicesite, frameshift, nonsense and missense mutations.2
We report a novel mutation identified in the CHM gene
of one affected male in a Turkish family, along with
related ocular findings.
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The patient had no siblings, and there were no known
problems on the paternal side of his family. His mother
also reported difficulty seeing in low light situations,
although it did not seem to affect her functionality. She
was noted to have pigmentary changes on fundus
photographs taken in Turkey, along with normal findings
on optical coherence tomography (OCT) and microperimetry (MP). Her own mother (the patient's maternal
grandmother) also complained of poor night vision. She
had 2 sisters, both of whom were healthy and had no
visual problems. One of the sisters had an 18-year son
who did not have any visual problems. The remainder of
the family history was unremarkable, and consanguinity
was denied. Figure 1 describes the patient's pedigree.
On examination, the patient's best-corrected visual
acuity was 20/20 in both eyes. Intraocular pressure was
10 mmHg in both eyes, extraocular movements were
intact, visual fields were full to confrontation and pupils
were equal and reactive to light. Slit-lamp examination
was normal. Fundus examination revealed waxy pallor
of the optic discs along with pigmentary changes and
retinal atrophy in both eyes.
OCT demonstrated peripheral loss of outer retinal layers
(including the inner segment/outer segment junction
and the retinal pigment epithelium) in all quadrants,
sparing the fovea (Figure 2A). Fundus autofluorescence
revealed a central island of preserved autofluorescence
surrounded by absent autofluorescence (Figure 2C). MP
demonstrated retinal sensitivity losses within the central
20 degrees (Figure 2D). Goldmann visual fields showed
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Figure 1: Pedigree of a family with choroideremia. Case IV-1 is the proband
and is genetically confirmed. Cases III-3 and II-3 are presumed to be carriers
for the mutation.

circumferentially constricted fields (below 20 degrees
radius) for all isopters, with temporal peripheral and
nasal mid-peripheral crescents of vision (Figure 2E).
Full-field electroretinogram demonstrated extinguished
rod and cone responses, and dark adaptometry
detected an elevated adaptation threshold.
After informed consent was obtained, genomic DNA was
extracted from leukocytes of peripheral blood. PCR
amplification were carried out at the Casey Institute
(CEI) (Portland, OR, USA). Subsequent sequencing was
performed at Seqwright Inc. (Houston, TX, USA). Direct
testing for mutation in the CHM gene was performed by
PCR amplification and DNA sequencing in two directions
of all coding exons and exon/intron boundaries. PCR
amplification utilised the forward primer 5'-CAAATTCT
GTTCCAAAATTAAATCC-3' and reverse primer
5'-CAACTGTAATAACTGCCCCCTTT-3'. Amplification
occurred at 96°C for 3 mins; 94°C for 30s; 10 cycles at
55-65°C for 30s; 72°C for 30s; 94°C for 30s; 30 cycles
at 55°C for 30s; 72°C for 30s; 4°C hold in an Applied
Biosystems 2720 Thermocycler (Thermo Fisher
Scientific, Halethorpe, MD, USA). The PCR product was
purified and then subjected to 96-Well High-Throughput
DNA sequencing by Seqwright Inc. Sequencing was
performed on a bank of ABI Prism 3730xl DNA
sequencers (Applied Biosystems) after being subjected
to the BigDye Terminator reagent kit. Codon 1
corresponded to the start ATG and nucleotide 1 to the A.
The reference sequence for CHM was NM_000390.2 '
NP_000381.1. The sensitivity of DNA sequencing was
99% for the detection of nucleotide base changes, small
deletions and insertions in the regions analysed.
678

Figure 2: Imaging of a Turkish patient with choroideremia. (A) SpectralDomain Optical Coherence Tomography demonstrates peripheral loss of
outer retinal layers (including the inner segment/outer segment junction and
the retinal pigment epithelium). (B) Infrared Reflectance imaging. (C) Fundus
Autofluorescence reveals a central island of preserved autofluorescence
surrounded by absent autofluorescence. (D) Microperimetry demonstrates
retinal sensitivity losses. (E) Goldmann Visual Fields show circumferentially
constricted fields (below 20 degrees radius) for all isopters, with temporal
peripheral and nasal mid-peripheral crescents of vision.

The patient possessed a novel nonsense mutation in the
CHM gene, namely p.E480X: c.1438G >T. The mutation
causes a premature stop codon in exon 12.

DISCUSSION
Choroideremia is a rare genetic disorder caused by
mutations in the CHM gene. The CHM gene has been
mapped to Xq21.1-q21.3, consists of 15 exons and
encodes an intracellular protein known as REP-1.
REP-1 is involved in the regulation of intracellular vesicle
transport and posttranslational modification in lipid
prenylation. It is actively expressed in ocular tissues
such as retina, choroid, and RPE. Deficiency of REP-1
results in disruption of intracellular transport and
premature cell death.3 Thus, CHM mutations causing
loss of function lead to progressive chorioretinal
degeneration.
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Clinically, the disease manifests as nyctalopia and
reduced peripheral vision followed by loss of visual
acuity that may result in legal blindness by the fourth
decade of life.1 Even though most patients with
choroideremia have a characteristic phenotype,
especially the distinctive autofluorescence appearance
as seen in this patient, in some cases it can be difficult
to clinically differentiate the disease from other
peripheral inherited retinal degenerations such as
retinitis pigmentosa.4 Genetic sequencing can confirm
the diagnosis and identify up to 94% of causative
mutations, the majority of which are null mutations. This
is particularly important because patients with null
mutations may benefit from gene replacement therapy,
which is being actively tested and has shown promising
results so far.5 Therefore, genetic testing is an important
modality in the management of choroideremia patients
and will likely play a larger role in the future.
The most common types of mutations identified by
genetic testing include insertions or deletions, single
point mutations, and mutations that affect splicing. Most
small mutations are located earlier in the 700 to 900
region, since it has a higher number of CpG sites where
C to T transition can result in a premature stop codon
and significantly truncate the protein. We report a novel
nonsense mutation in the CHM gene in a Turkish man
with choroideremia, p.E480X: c.1438G >T. The mutation
causes a premature stop codon in exon 12 and is
predicted to lead to a null effect. According to the
American College of Medical Genetics and Genomics
and the Association for Molecular Pathology 2015
guidelines, this null variant is very likely to be pathogenic

since loss of function is a known mechanism for choroideremia.
We believe that the patient's mother and maternal
grandmother were heterozygous for the mutation.
Carriers of choroideremia are usually asymptomatic but
may display variable severity of the disease depending
on the lyonisation in the retinal cells. Given the patient's
pedigree, family history, and genetic results, the mother
was presumed to be a carrier for the mutation and it was
deemed unnecessary to test her.
This is the first report of a G1438T mutation resulting in
an E480X premature stop in the CHM gene in a Turkish
male with choroideremia.
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